AU Patent

AU2019200222B2 — Treatment of cancers using PI3 kinase isoform modulators

Assigned to Infinity Pharmaceuticals Inc · Expires 2020-07-02 · 6y expired

What this patent protects

Provided herein are methods, kits, and pharmaceutical compositions that include a P13 kinase inhibitor for treating cancers or hematologic disorders.

USPTO Abstract

Provided herein are methods, kits, and pharmaceutical compositions that include a P13 kinase inhibitor for treating cancers or hematologic disorders.

Drugs covered by this patent

Patent Metadata

Patent number
AU2019200222B2
Jurisdiction
AU
Classification
—
Expires
2020-07-02
Drug substance claim
No
Drug product claim
No
Assignee
Infinity Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.